Development of a surrogate potency assay to determine the angiogenic activity of Stempeucel®, a pooled, ex-vivo expanded, allogeneic human bone marrow mesenchymal stromal cell product
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Mesenchymal stromal cells (MSCs) have emerged as a more beneficial alternative to conventional therapy and may offer a potential cure for unmet medical needs. MSCs are known to possess strong immunomodulatory and anti-inflammatory properties. Moreover, they promote angiogenesis and tissue regeneration through the secretion of trophic factors. For these reasons, the past decade witnessed a sharp increase in the number of clinical trials conducted with stem cells for various vascular diseases requiring angiogenesis. In this study, we evaluated the in vitro angiogenic potency of Stempeucel®, which is an allogeneic pooled human bone marrow-derived mesenchymal stromal cell (phBMMSC) product. We previously established the safety of Stempeucel® in our pre-clinical studies, and clinical trials conducted for critical limb ischaemia and acute myocardial infarction. METHODS: Because the proposed mechanism of action of phBMMSCs is mainly through the secretion of pro-angiogenic cytokines, we developed a surrogate potency assay by screening various batches of large-scale expanded phBMMSCs for the expression of angiogenic factors and cytokines through gene expression and growth factor analyses, followed by in vitro functional assays. RESULTS: The well characterized angiogenic vascular endothelial growth factor (VEGF) was selected and quantified in twenty six manufactured batches of phBMMSCs to establish consistency following the United States Food and Drug Administration recommendations. According to recommendations 21 CFR 211.165(e) and 211.194(a)(2), we also established and documented the specificity and reproducibility of the test methods employed through validation. Moreover, we also attempted to elucidate the mechanism of action of the cell population to ensure appropriate biological activity. The functional role of VEGF has been established through in vitro angiogenic assays and a dose-dependent correlation was observed with in vitro functional results. CONCLUSIONS: The data generated from this study suggest the selection of VEGF as a single surrogate marker to test the angiogenic potency of phBMMSCs. Our study reports the quantification of VEGF in twenty six batches of large-scale manufactured phBMMSCs, and a concentration-dependent correlation of secreted VEGF to endothelial cell functions of migration, proliferation and tube formation, in the conditioned medium obtained from nine phBMMSC batches. To our cognizance, this is the first study in which a single angiogenic factor (VEGF) has been qualified as a surrogate potency marker through all three in vitro functional assays to determine the angiogenic potency of the phBMMSC population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“For instance, dose-dependent levels of VEGF from BM-MSC secretomes have been correlated with angiogenic activity and proposed as a surrogate potency assay for clinical preparations [45].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Risau, W. (1997) · Nature · doi:10.1038/386671a0 · Cited by 5,727
The Biology of Vascular Endothelial Growth Factor
Ferrara, N., & Davis-Smyth, T. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.1.0287 · Cited by 4,330
Vascular-specific growth factors and blood vessel formation
Yancopoulos, G. D., Davis, S., Gale, N. W., Rudge, J. S., Wiegand, S. J., & Holash, J. (2000) · Nature · doi:10.1038/35025215 · Cited by 3,699 · cited 1×
“In tissues requiring revascularization, endothelial cells migrate, proliferate and differentiate to form primitive tubular networks, which are regulated by proangiogenic growth factors and cytokines [2].”
BackgroundAsahara, T., Masuda, H., Takahashi, T., Kalka, C., Pastore, C., Silver, M., Kearne, M., Magner, M., & Isner, J. M. (1999) · Circulation Research · doi:10.1161/01.res.85.3.221 · Cited by 3,253
Takahashi, T., Kalka, C., Masuda, H., Chen, D., Silver, M., Kearney, M., Magner, M., Isner, J. M., & Asahara, T. (1999) · Nature Medicine · doi:10.1038/7434 · Cited by 2,423
Vascular Endothelial Growth Factor and Angiogenesis
Hoeben, A., Landuyt, B., Highley, M. S., Wildiers, H., Van Oosterom, A. T., & De Bruijn, E. A. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.4.3 · Cited by 1,824
Tateishi-Yuyama, E., Matsubara, H., Murohara, T., Ikeda, U., Shintani, S., Masaki, H., Amano, K., Kishimoto, Y., Yoshimoto, K., Akashi, H., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09670-8 · Cited by 1,734
Mesenchymal Stem Cells Enhance Wound Healing Through Differentiation and Angiogenesis
Wu, Y., Chen, L., Scott, P. G., & Tredget, E. E. (2007) · Stem Cells · doi:10.1634/stemcells.2007-0226 · Cited by 1,676
Signal transduction by vascular endothelial growth factor receptors
Koch, S., Tugues, S., Li, X., Gualandi, L., & Claesson-Welsh, L. (2011) · Biochemical Journal · doi:10.1042/bj20110301 · Cited by 1,635
Mesenchymal Stem Cells Can Be Differentiated Into Endothelial Cells In Vitro
Oswald, J., Boxberger, S., Jørgensen, B., Feldmann, S., Ehninger, G., Bornhäuser, M., & Werner, C. (2004) · STEM CELLS · doi:10.1634/stemcells.22-3-377 · Cited by 1,317
Cited by
Mesenchymal stromal cell therapy: progress in manufacturing and assessments of potency
ROBB, K. P., FITZGERALD, J. C., BARRY, F., & VISWANATHAN, S. (2019) · Cytotherapy · doi:10.1016/j.jcyt.2018.10.014 · Cited by 156
Bhat, S., Viswanathan, P., Chandanala, S., Prasanna, S. J., & Seetharam, R. N. (2021) · Scientific Reports · doi:10.1038/s41598-021-83088-1 · Cited by 139
The issue of heterogeneity of MSC-based advanced therapy medicinal products–a review
Česnik, A. B., & Švajger, U. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1400347 · Cited by 128
Adaş, G., Çukurova, Z., Yaşar, K. K., Yılmaz, R., Işıksaçan, N., Kasapoğlu, P., Yeşilbağ, Z., Koyuncu Irmak, D., & Karaöz, E. (2021) · Cell Transplantation · doi:10.1177/09636897211024942 · Cited by 97
Mabotuwana, N. S., Rech, L., Lim, J., Hardy, S. A., Murtha, L. A., Rainer, P. P., & Boyle, A. (2022) · Stem Cell Reviews and Reports · doi:10.1007/s12015-022-10429-6 · Cited by 93
Metadata
- Authors
- Thej, C., Ramadasse, B., Walvekar, A., Majumdar, A. S., & Balasubramanian, S.
- Affiliations
- Manipal Academy of Higher Education (IN)
- Stempeutics (India) (IN)
- Corresponding author
- Majumdar, Anish S.
- Balasubramanian, Sudha
- Venue
- Stem Cell Research & Therapy
- Published
- 2017-02-28
- Volume
- 8
- Issue
- 1
- Pages
- 47-47
- ISSN
- 1757-6512 (ISSN-L)
- PMC
- PMC5331748
- OpenAlex
- W2592283567
- Cited by
- 35
- References
- 45
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 5 · 2023: 8 · 2022: 5 · 2021: 7 · 2020: 1 · 2019: 2 · 2018: 4
- FWCI
- 1.10
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Stem Cell Research & Therapy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Dentistry › Periodontics › Periodontal Regeneration and Treatments
- Keywords
- mesenchymal stem cells, vascular endothelial growth factor, ex vivo cell expansion, critical limb ischemia, acute myocardial infarction, angiogenesis, endothelial tube formation, conditioned medium
- MeSH terms
- Biological Assay, Bone Marrow Cells, Cell Movement, Humans, Ribonuclease, Pancreatic, Transplantation, Homologous, Interleukin-6, Gene Expression, Interleukin-8, Culture Media, Conditioned, Hepatocyte Growth Factor, Vascular Endothelial Growth Factor A, Angiogenesis Inducing Agents, Mesenchymal Stem Cell Transplantation, Cell Proliferation, Transforming Growth Factor beta1, Chemokine CXCL12, Mesenchymal Stem Cells, Primary Cell Culture, Human Umbilical Vein Endothelial Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Development of a surrogate potency assay to determine the angiogenic activity of Stempeucel®, a pooled, ex-vivo expanded, allogeneic human bone marrow mesenchymal stromal cell product. https://app.cochat.ai/papers/10.1186/s13287-017-0488-3
- The paper
- Thej, C., Ramadasse, B., Walvekar, A., Majumdar, A. S., & Balasubramanian, S. (2017). Development of a surrogate potency assay to determine the angiogenic activity of Stempeucel®, a pooled, ex-vivo expanded, allogeneic human bone marrow mesenchymal stromal cell product. Stem Cell Research & Therapy. https://doi.org/10.1186/s13287-017-0488-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.